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Abstract
Antibody-mediated rejection (AMR) caused by donor-
specific anti-human leukocyte antigen antibodies (DSA) 
is widely accepted to be a risk factor for decreased 
graft survival after kidney transplantation. This entity 
also plays a pathogenic role in other solid organ 
transplants as it appears to be an increasingly common 
cause of heart graft dysfunction and an emerging issue 
in lung transplantation. In contrast, the liver appears 
relatively resistant to DSA-mediated injury. This 
“immune-tolerance” liver property has been sustained 
by a low rate of liver graft loss in patients with 
preformed DSA and by the intrinsic liver characteristics 
that favor the absorption and elimination of DSA; 
however, alloantibody-mediated adverse consequences 
are increasingly being recognized, and several cases of 
acute AMR after ABO-compatible liver transplant (LT) 
have been reported. Furthermore, the availability of 
new solid-phase assays, allowing the detection of low 
titers of DSA and the refinement of objective diagnostic 
criteria for AMR in solid organ transplants and 
particularly in LT, have improved the recognition and 
management of this entity. A cost-effective strategy of 
DSA monitoring, avoidance of class Ⅱ human leukocyte 
antigen mismatching, judicious immunosuppression 
attached to a higher level of clinical suspicion of AMR, 
particularly in cases unresponsive to conventional anti-
rejection therapy, can allow a rational approach to this 
threat.
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TOPIC HIGHLIGHT
Clinical significance of donor-specific human leukocyte 
antigen antibodies in liver transplantation
2015 Advances in Liver Transplantation
Antonio Cuadrado, David San Segundo, Marcos López-Hoyos, Javier Crespo, Emilio Fábrega
Core tip: The role of donor-specific anti-human leukocyte 
antigen antibodies (DSA) in liver transplant (LT) remains 
unclear. Alloantibody-mediated adverse consequences 
are increasingly being recognized, and several cases of 
acute antibody-mediated rejection after ABO-compatible 
LT have been reported. There is a need to investigate 
and quantify the potential adverse impact of DSA on LT 
outcomes. The present review addresses the current 
knowledge on this issue.
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INTRODUCTION
Although human leukocyte antigen (HLA) antibodies 
(Abs) have been more extensively studied in kidney 
transplantation, they can be detected after any solid 
organ transplantation. As with renal transplantation, 
the presence of anti-HLA Abs in heart and lung 
transplants is associated with a worse graft survival[1]. 
The impact of donor-specific anti-HLA antibodies (DSA) 
on short- and long-term liver transplant (LT) outcome 
is not clearly defined. In LT, the presence of preformed 
DSA is well recognized, although in most cases, DSA 
disappear a few months after liver transplantation. 
In the setting of DSA persistence and evidence of 
complement activation after LT, no significant clinical 
impact in the first year post-transplantation has been 
described[2]; however, recent reports indicate that 
some LT recipients who develop de novo DSA result in 
lower graft survival and patient survival[3-7]. Thus, there 
is a need to investigate and quantify the potential 
adverse impact of DSA on LT outcomes. The present 
review addresses the current knowledge on this issue 
with a particular focus on LT.
IMPORTANCE OF ANTIBODY-
MEDIATED REJECTION IN SOLID ORGAN 
TRANSPLANTATION
The detrimental effects of DSA on renal transplantation 
outcomes have been recognized since 1969[8], and 
since then, strong evidence has indicated longer 
kidney allograft survival among patients without DSA. 
In this setting, the incidence of hyperacute rejection 
caused by pre-existing DSA has been nearly eliminated 
by performing a complement-dependent cytotoxic 
cross-match prior to kidney transplantation; however, 
acute and chronic antibody-mediated rejection (AMR) 
plays an increasingly critical role in kidney allograft loss 
and is considered among the most important barrier 
that limits long-term outcomes[9-14]. In 2003, at the 
National Institutes of Health conference, acute AMR in 
renal transplantation was defined as an acute rejection 
with graft dysfunction, histological evidence of acute 
tissue injury and C4d deposition in the presence of 
DSA[15]. 
The negative impact of alloantibodies directed 
against donor HLA antigens was subsequently widely 
demonstrated and accepted not only in kidney but also 
in heart transplant, and recent evidence also endorses 
this notion in pancreatic and lung transplantation[16-24]. 
For instance, whereas the incidence and mortality 
of cardiac acute cellular rejection (ACR) have de-
creased in recent years as a result of advances in 
immunosuppression, the incidence of AMR appears 
to be increasing[25]. Furthermore, AMR also seems to 
be an increasingly common cause of graft dysfunction 
and cardiac allograft vasculopathy[26,27]. In fact, 
the presence of DSA in these types of solid organ 
transplant may contraindicate the transplant due 
to the increased risk of acute rejection and lower 
graft survival[28-30]. Moreover, in these patients the 
development of de novo DSA after transplantation 
has also been associated with an increased risk of 
rejection and lower survival[22,24,31,32]. As a consequence 
of the above-mentioned problems, different strategies-
from prevention, DSA monitoring, and selection of 
adequate immunosuppressive regimens to therapeutic 
approaches-have been adopted to minimize the 
deleterious effects of AMR. In the next sections we will 
focus on these factors. 
ANTIBODY-MEDIATED REJECTION IN 
LIVER TRANSPLANTATION
Human liver allografts are highly resistant to acute 
AMR from preformed human HLA alloantibodies 
in comparison with kidney allografts[33]. In LT, the 
presence of preformed DSA is well recognized, although 
in most cases, DSA disappear a few months after 
liver transplantation. Several separate mechanisms 
in isolation or in combination have been postulated 
to explain this state of “immune privilege” in the 
LT setting[34,35]: (1) the liver secretes soluble HLA 
class I molecules that form immune complexes with 
alloantibodies, which are then cleared by Kupffer cells; 
(2) Kupffer cell phagocytosis of platelet aggregates and 
immune-complexes limits complement activation; (3) 
the limited distribution of HLA class Ⅱ expression in the 
microvasculature; (4) the great liver restorative and 
regenerative capacity before any insult, even mediated 
by the immune system; and (5) a large endothelial 
surface that is capable of absorbing circulating Abs. 
For example, in a rat model, DSA are cleared from 
the circulation in only 30 min when the serum is 
perfused through an extracorporeal liver of donor 
origin[36]. Other possible mechanisms proposed are 
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related to the particular coagulation state in advanced 
liver diseases (the deficit of coagulation factors and 
thrombocytopenia-related portal hypertension can help 
reduce platelet aggregates and hence the formation 
of vascular thrombosis observed in humoral rejection 
mediated by DSA) that can facilitate the vascular flow, 
the hypocomplementemia of liver cirrhosis, and the dual 
hepatic vasculature that facilities improved flow during 
injury. This factor may decrease hepatic necrosis from 
arterial vasospasm and local intrahepatic coagulation 
that occur as result of DSA[34].
However, in the last years there have been different 
reports that highlight a potential deleterious role 
of preformed HLA Abs in liver graft survival[5,37-53]. 
Kozlowski et al[40] found that preformed DSA that 
persists after LT was associated with severe early 
rejection. Moreover, Krukemeyer et al[54] have re-
vealed portal infiltration and proliferation of B lym-
phocytes (CD20) and plasma cells (CD138) as well 
as the expression of the B cell/plasma cell-activating 
chemokines MIP-3, CXCL9, CXCL10, CXCL11, and 
CXCL12 in acute liver allograft rejection. Recently, O’
Leary et al[38] have found AMR to be a contributor to 
previously unexplained early liver allograft loss through 
the analysis of 60 patients with idiopathic early allograft 
loss when strict criteria for AMR diagnosis were fulfilled. 
The authors concluded that liver allograft recipients 
with preformed DSA with a high mean fluorescence 
intensity (MFI) seem to be at risk for clinically 
significant allograft injury and possibly for loss from 
AMR, often in combination with ACR. In addition, Musat 
et al[39] demonstrated that DSA is present in up to 
75% of patients experiencing rejection, and both DSA 
and C4d staining was present in 54% of the patients 
diagnosed with ACR, demonstrating a previously 
unrecognized humoral component to these rejections. 
Furthermore, in this study 70% of the patients with 
ductopenia had DSA and 60% of the ductopenia cases 
had both circulating DSA in association with diffuse 
portal C4d deposition, supporting a role for AMR 
in the pathogenesis of interlobular bile duct injury 
and loss[39]. These results have been corroborated 
in other studies[31,37,40,51,55-59]. Morphometric studies 
have shown that portal tract microvasculature 
destruction precedes bile duct loss in the process of 
liver allograft rejection[38,57]. Thus, the following chain 
of events seems to occur: the formation of the DSA-
HLA complex on endothelial cells of the portal tract 
microvasculature triggers complement activation 
(evidenced by C4d deposition) and destruction of 
the portal microvasculature/capillaries branching off 
the communicating artery from which the periductal 
vascular plexus arises[60], resulting in ischemic bile duct 
injury and loss. In fact, the resolution of cholestasis 
and ductopenia in association with a reduction of C4d 
deposition only after a decrease in circulating DSA 
with aggressive therapy specifically directed towards 
antibody removal further supports this role.
Certainly, no associations between donor-
specific HLA alloantibodies with outcomes in liver 
or simultaneous liver-kidney transplant recipients 
(SLKT) have been demonstrated in large, randomized 
clinical trials[34]. Nonetheless, a panel of experts 
gathered in a recent meeting to discuss the different 
aspects regarding the consequences of DSA in liver 
transplantation agree that both acute AMR in liver 
transplantation recipients and an antibody-mediated 
renal allograft rejection observed in SLKT are two 
accepted associations on the basis of multiple case-
control studies[34].
Regarding SLKT, “renal allograft protection” by 
the liver allograft occurs when the recipient harbors 
isolated preformed class Ⅰ DSA in low-to-moderate 
amounts[34]; however, inferior outcomes have been 
demonstrated when preformed high MFI class Ⅱ DSA 
is present[61,62]. In those cases, both the kidney and 
liver allografts are at a risk for rejection, especially 
when class Ⅱ DSA persists post-transplantation[62,63]. 
Patients who undergo SLKT should ideally receive 
organs without class Ⅱ antigens against which the 
recipient has DSA with an MFI > 5000.
Other potential associations described include the 
following: hyperacute rejection[64], de novo autoimmune 
hepatitis[65], anastomotic biliary strictures[66], and 
idiopathic fibrosis progression[60,67] (Figure 1).
DE NOVO DSA IN LIVER 
TRANSPLANTATION
The role of de novo DSA after LT remains unclear as 
the majority of studies have focused on preformed 
DSA. The risk of DSA development increases with 
a low immunosuppression load[60]. Infections and 
inflammatory events could alter the expression of 
class-Ⅰ and class-Ⅱ antigens and hence contribute 
to alloresponse induction and DSA development[68-70]. 
A recent report demonstrated that 8.1% of a cohort 
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Hyperacute rejection
Acute antibody-mediated rejection
Early acute “cellular” rejection
Steroid-resistant rejection
Antibody-mediated renal allograft rejection in 
simultaneous liver-kidney transplant recipients
Chronic rejection
Idiopathic fibrosis progression
Accelerated fibrosis in hepatitis C virus
De novo  autoimmune hepatitis
Anastomotic biliary strictures
Portal venopathy and nodular regenerative hyperplasia
D
SA
Figure 1  Potential associations of donor-specific human leukocyte 
antigen antibodies with outcomes in liver transplant or simultaneous 
liver-kidney transplant recipients. No associations have been confirmed in 
large randomized controlled trials. Adapted from O'Leary et al[34]. HLA: Human 
leukocyte antigen; DSA: Donor-specific anti-HLA antibodies.
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issues could explain the fibrosis such as subclinical 
biliary obstruction or venous flow, recent publications 
have confirmed the observations of Miyagawa-
Hayashino (Table 1 and Figure 2)[58,72,79].
MECHANISMS OF ANTIBODY-MEDIATED 
REJECTION
The mechanisms involved in the DSA-mediated graft 
damage (inflammation, necrosis and fibrosis) can 
be summarized as follows[17-19]: (1) the complement 
activation by the classical pathway that induces 
complex formation of the membrane attack (indirectly 
detected using immunohistochemistry for C4d 
-a degradation product of C4, present at the site 
of complement activation- attached to vascular 
endothelium); (2) direct damage to the vascular 
endothelial capillaries through the interaction of the 
Abs to HLA and non-HLA antigens expressed on their 
cell surface; (3) platelet activation and aggregation 
causing the release of their granules containing 
growth factors, cytokines, chemokines and adhesion 
molecules that promote the recruitment and activation 
of pro-inflammatory cells; and (4) the DSA facilitate 
the activation of pro-inflammatory cells such as 
natural killer (NK) cells, macrophages and neutrophils, 
which express at their surface the receptor for the 
crystallizable fragment (Fc) of immunoglobulin (Figure 
3). This cascade of events is morphologically translated 
by the observation of platelet aggregates, neutrophil 
accumulation, and microangiopathic thrombosis, 
causing cell necrosis and early graft failure. Chronic 
antibody-mediated rejection is due to repetitive 
thrombotic events and inflammatory phenomena 
culminating in fibrotic changes. The following path-
ological damages have been described after liver tran-
splantation: platelet aggregates in the portal and/or 
centrilobular areas, neutrophil infiltration, patchy 
necrosis and centrilobular hepatocyte ballooning, 
cholangiolar proliferation, acute cholangiolitis and cho-
lestasis[6,50,51,80].
DIAGNOSIS OF DSA-RELATED AMR
Because of the overwhelming evidence for antibody-
of 749 LT recipients developed de novo DSA one year 
after transplantation (most of them against HLA-Ⅱ, 
especially HLA-DQ)[5]. De novo DSA resulted in lower 
graft and patient survival in a multivariate analysis. 
These findings were confirmed by Fontana et al[71] 
Moreover, 75% of the patients who developed de novo 
DSA had biliary complications. Furthermore, O’Leary 
et al[49] have shown the clinical relevance of de novo-
specific antibodies on rejection and long-term survival. 
In addition, a higher rate of the novo DSA, especially 
of HLA-class-Ⅱ, in pediatric patients with chronic 
rejection has recently been observed[72]. 
IDIOPATHIC FIBROSIS PROGRESSION
Evidence has shown that the humoral alloresponse 
may have a role in interstitial fibrosis and tubular 
athropy development after kidney transplantation[73]. 
In LT, graft fibrosis is frequently observed in late 
biopsies from pediatric patients with a normal or mild 
hepatic profile, and the severity of fibrosis correlates 
with the timing from LT to biopsy[74-77]. Miyagawa-
Hayashino et al[78] are the first to suggest a role of 
DSA and the humoral response in long-term fibrosis 
in LT. The LT patients with de novo DSA and normal 
graft function had a higher grade of fibrosis and 
inflammation with a C4d-positive biopsy than patients 
free of DSA. Importantly, this study showed an 
association between DSA and fibrosis, but the cause-
effect was not demonstrated. Although other potential 
Ref. No. of patients Positive for HLA 
Abs







Miyagawa-Hayashino et al[78]   79 32 LD 11 After LT SAB > 5000
Salah et al[58] 114   5 LD 2 After LT SAB > 5000
O´Leary et al[60] 507 46 DD 6.4 Pre and after LT SAB > 5000
Grabhorn et al[72]   19 16 LD + DD 4.5 After LT SAB > 5000
Iacob et al[79] 174 34 LD + DD ND After LT SAB > 5000
HLA: Human leukocyte antigen; DSA: Donor-specific anti-HLA antibodies; SAB: Single-antigen-bead; MFI: Mean fluorescence intensity; LT: Liver transplant.
Table 1  Association of graft fibrosis and concomitant anti-human leukocyte antigen class Ⅱ donor-specific anti-human leukocyte 
antigen antibodies
Graft injury (normal or mild hepatic profile)
Diffuse portal C4d detectable in the liver graft
Preformed or de novo  DSA detectable in circulation after LT
Liver transplant                           Time                                 Graft lost
Idiopathic fibrosis progression
Figure 2  Idiopathic fibrosis progression. Hypothetical chain of events. DSA: 
Donor-specific anti-HLA antibodies; LT: Liver transplant.
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mediated injury to kidney allografts, a consensus 
conference was held in 2003 to define the diagnostic 
criteria for antibody-mediated rejection in solid 
organ transplantation[15]. This group developed 
diagnostic criteria for AMR after kidney, heart or lung 
transplantation. Accordingly, the diagnosis of AMR 
requires clinical evidence of graft dysfunction, histologic 
evidence of tissue injury, immunopathologic evidence 
of an antibody response [complement component 4d 
(C4d) or immunoglobulin deposition] and serologic 
evidence of anti-HLA or anti-donor antibody at the 
time of biopsy. 
In the setting of liver transplantation there are 
stringent criteria for the diagnosis of acute AMR that 
include the following (Table 2)[34,38]: (1) the presence 
of DSA in the serum; (2) histopathologic evidence 
of diffuse microvascular endothelial cell injury and 
microvasculitis; (3) strong and diffuse C4d positivity 
in the tissue; and (4) reasonable exclusion of other 
causes of injury that might result in similar findings.
Pre-transplantation cross-matching of the recipient’s 
serum and the donor’s lymphocytes has become a 
requirement of kidney transplant programs throughout 
the world on the basis of the known deleterious 
effects on kidney allografts of antibody-mediated 
graft injury[81]. In the setting of LT, there is a need to 
develop a cost-effective DSA monitoring algorithm, 
but a panel of experts has recently recommended a 
DSA monitoring schedule that includes testing all liver 
allograft recipients in the pre-transplant setting and, 
afterwards retesting all positive patients 1-2 wk post-
transplantation to determine persistence[34]. There have 
been notable technological advances in the available 
assays to determine DSA. Earlier cell-based assays for 
DSA detection (i.e., cytotoxic crossmatch) had several 
limitations in terms of sensitivity and specificity and 
the ability to differentiate between IgG from IgM Abs 
and between HLA from non-HLA Abs. Flow cytometry 
cross-matching is another cell-based assay that relies 
on the detection of Abs binding to the surface of donor 
Figure 3  Mechanisms involved in humoral graft damage. Early post transplantation after ischemia/reperfusion injury (a) the endothelium can release several 
chemokines and cytokines to gather innate immune cells as neutrophils, macrophages. In this inflammatory setting, the graft endothelium could be activated and 
expressed human leukocyte antigen (HLA) class-Ⅱ antigens (b), subsequently, these antigens could be recognized by anti-HLA class-Ⅱ antibodies. If the antibodies 
are able to fix complement factors could trigger classical complement pathway that finally induce the membrane attack complex (c) on targeted endothelial cells. 
During complement activation, C4a component is degraded in C4d and finally deposited on capillaries. After destruction of endothelial cells, the HLA class-Ⅱ 
molecules could be released and directly detected by circulating anti-HLA antibodies that once recognized by FC receptors on NK cells could direct cytotoxic actions 
and cytokine production. Another potential mechanism of humoral graft damage could be driven by platelet activation and thrombi formation (e).
Table 2  Diagnostic criteria of acute antibody-mediated 
rejection in liver transplantation
The presence of DSA in serum
Histopathologic evidence of diffuse microvascular endothelial cell 
injury and microvasculitis
Strong and diffuse C4d positivity in tissue1
Reasonable exclusion of other causes of injury that might result in 
similar findings
1Diffuse portal microvascular positivity in formalin-fixed, paraffin-
embedded samples (although detection of C4d is more sensitive in fresh 
tissue) is emerging as most strongly correlated with donor-specific anti-
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lymphocytes and is more sensitive than cytotoxic 
crossmatch. The first solid-phase immunoassay 
(SPI) used to test anti-HLA Abs was based on an 
enzyme-linked immune assay (ELISA), but recently 
SPI is being replaced by single-antigen-bead (SAB) 
assays. Acquired by LuminexTM, this technology offers 
a new approach in the detection and quantification 
of post-transplantation anti-HLA Abs, which can be 
present in any solid transplant. This immunoassay 
allows the detection of low titters of HLA Abs that 
were undetectable by former assays, specifically and 
semiquantitatively[23,34,81]. The fluorescence signals 
detected are expressed as MFI or molecules of 
equivalent soluble fluorochrome (MESF). The isolated 
finding of HLA DSA is not specific for AMR because 
it has been found in 60% of LT recipients without 
rejection[37]. Certainly, most patients with preformed 
low-to-moderate levels of isolated class Ⅰ DSA in the 
absence of recurrent liver disease appear to have few, 
if any, short- or long-term consequences. Moreover, 
the significance of DSA late after liver transplantation 
without allograft dysfunction is uncertain[34]. As an 
isolated finding it does not represent an indication for 
intervention, although the long-term outcomes of such 
patients are thus far unknown.
C4d is a component of the complement cascade 
that is considered a marker of complement regulation. 
The complement system is a part of the innate 
immunological response and becomes activated in a 
variety of immunological events, such as ACR and viral 
and autoimmune hepatitis[82,83]. Different C4d staining 
patterns have been described in liver allografts. Even 
diffuse endothelial and sinusoidal C4d staining alone 
cannot be considered specific for the diagnosis of 
AMR as it has been found in AMR and other common 
allograft disorders such as ACR, chronic rejection, 
biliary obstruction and recurrent viral or autoimmune 
hepatitis[50,84]. Although there is no consensus, the 
diffuse portal microvascular positivity in formalin-
fixed, paraffin-embedded samples (although detection 
of C4d is more sensitive in fresh tissue) is emerging 
to be most strongly correlated with DSA-induced 
injury[38-40,50,52,85]. Otherwise, C4d-negative AMR has 
been identified in renal allografts and likely occurs in 
the liver, although experts favor the above described 
conservative approach until more is learned about liver 
AMR[20,38].
Finally, the clinical presentation of liver allograft 
AMR is nonspecific, and many etiologies, such as ACR, 
ischemic injury, pharmacological toxicity, infections, 
initial graft dysfunction, hepatic artery thrombosis, 
biliary complications, and disease recurrence, can 
explain increases in aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), and cholestasis[59,86,87]. 
AMR should be considered as part of the differential 
diagnosis if DSA are present. These observations have 
prompted the design of a multicenter study of specific 
features that could be used to screen patients for 
acute AMR via routine HE staining[88].
WHEN MUST AMR BE SUSPECTED? 
Acute AMR occurs most commonly during the first 
several weeks after liver transplantation and consists 
of an otherwise unexplained liver allograft dysfunction 
associated with falling platelets and complement levels 
and increased levels of circulating immune complexes 
in patients with preformed, persistent DSA[67]. The 
liver biopsy shows microvascular injury in addition to 
other characteristics associated with allograft rejection, 
which is observed in approximately 1% of all early (< 
90 d) liver allograft failures. Notwithstanding, acute 
AMR could explain up to 10% of idiopathic early liver 
allograft failures in DSA-positive patients[38]. 
Therefore, a high suspicion of DSA-induced AMR 
would theoretically be raised for a liver recipient with 
high titers of preformed anti-donor HLA class Ⅱ Abs 
who presents graft dysfunction in the early post-
transplant period (first 90 d) that is otherwise not 
explained and is associated with falling platelets and 
complement levels and increased levels of circulating 
immune complexes. Furthermore, a negative res-
ponse to conventional antirejection therapy is also 
associated[89]. SLKT recipients who receive crossmatch-
positive organs are also the patients in which a high 
level of alert must be maintained, especially when 
the recipient has DSA with an MFI > 5000[62,63]; 
however, as stated above, there are other possible 
clinical presentations where DSA can play a pathogenic 
effect and thus could indicate the use of a diagnostic 
approach (i.e., DSA assay, liver biopsy, etc.).
RISK FACTORS FOR DSA-RELATED AMR 
IN LIVER TRANSPLANT RECIPIENTS
Together with class Ⅱ HLA mismatching and prior 
cellular rejection, inadequate immunosuppression 
(particularly minimization and non-adherence to 
immunosuppressive medication) is a risk factor for the 
development of DSA[23]. 
Recognized risk factors favoring DSA-mediated 
liver damage were identified before the use of SAB 
technology allowed more accurate DSA determinations 
and included high-titer preformed Abs, the per-
sistence of anti-donor Abs after transplantation, and 
otherwise unexplained thrombocytopenia and hypo-
complementemia[38,51,65,90-92]. Thereafter, adverse 
outcomes have been associated with strongly positive 
flow cytometry cross-matches versus weakly positive 
cross-matches and strong preformed DSA evaluated 
for their complement fixing ability with a complement 
component 1q (C1q) assay[86]. C1q-binding DSA are 
expected to have the potential to assess cytotoxicity 
and have been associated with a greater risk of acute 
rejection and allograft lost in patients undergoing renal 
and heart transplantation[93-95]. Thus, in a recently 
proposed algorithm, a patient with strong DSA and 
C1q-positive DSA is considered at a higher risk and 
should be monitored for post-transplant DSA[59]. If 
Cuadrado A et al . DSA in liver transplantation
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persistent DSA are detected, the patient is monitored 
as being at a higher risk for AMR.
Furthermore, the effects of DSA can vary depending 
on cofactors, some of which may promote immune 
stimulatory/profibrogenic effects and some of which 
could promote tolerogenic effects[34]. Thus, on the one 
hand, the up-regulation of DSA targets in allografts 
of patients with infections or inflammatory-mediated 
tissue damage[68-70] as occurs in patients with recurrent 
hepatitis C chronic infection, as a consequence, 
appears to be associated with fibrosis progression[60]. 
On the other hand, HLA class Ⅱ-restricted regulatory 
T cell (Treg) epitopes in IgG (also called “Tregitopes”) 
that suppress immune responses to co-administered 
antigens may be formed as a result of DSA, thereby 
promoting tolerance[96].
PREVENTION AND MANAGEMENT OF 
LIVER DSA-RELATED AMR 
As previously mentioned, the advent of new diagnostic 
technologies, particularly SAB assays, has allowed 
the assessment of the immunological risk in potential 
recipients of a particular donor by means of the iden-
tification and characterization of HLA Abs. In the kidney 
transplant setting, a detailed serological follow-up is 
of critical importance in the decision-making process 
because it can help determine whether to proceed 
with the transplantation, desensitize or follow a 
standard immunosuppressive (IS) therapy[23]. Efficient 
desensitization protocols have enabled successful 
transplantations, overcoming immunological barriers in 
patients including the barrier of a positive complement-
dependent cytotoxic cross-match[97-99]. Anti-humoral 
therapy is based on two complementary approaches: 
(1) the removal of harmful Abs from the blood stream 
through plasmapheresis or immunoadsorption; and 
(2) the modulation of various components of specific 
and/or innate immunity using strategies including 
intravenous immunoglobulin, anti-CD20 antibody 
(rituximab), antithymocyte globulin (ATG), proteasome 
inhibitor (bortezomib), anti-C5 antibody (eculizumab), 
or even splenectomy[97-99]. 
In the setting of liver transplantation, the routine 
assessment of DSA pre-transplantation, with a retest 
of positive patients 1-2 wk post-transplantation, has 
been recommended by a panel of experts[34]. This 
fact is of particular interest when a SLKT is being 
considered and in the case of anti-donor HLA class 
Ⅱ Abs; however, there are several shortcomings 
with this strategy that need to be solved[34]: (1) only 
a small percentage of sensitized patients before 
transplantation will have severe, adverse consequences 
after transplantation; and (2) the significance of 
DSA late after liver transplantation without allograft 
dysfunction is uncertain and, in general, this finding 
does not merit any intervention. Taking into account 
these shortcomings, a panel of experts have recently 
proposed to investigate the design of cost-effective 
DSA monitoring strategies that allow one to detect 
the first group of patients and that identifies DSA 
characteristics late after transplantation that indicate 
inadequate immunosuppression or an unacceptable 
risk of chronic allograft injury[34]. 
Patients who undergo SLKT should ideally receive 
organs without class Ⅱ antigens against which the 
recipient has DSA with an MFI > 5000[34]; however, if a 
patient must receive cross-match positive organs after 
balancing the risks of a DSA-mediated rejection against 
those related to a protracted waiting list period in 
terms of progression of the liver disease, postoperative 
testing to determine antibody persistence and close 
follow-up are desirable[34].
Otherwise, the IS regimen and drug exposure can 
be relevant in terms of prevention of DSA-mediated 
allograft damage. In the kidney transplantation 
setting, the selection of an adequate IS can pre-
vent subclinical inflammation and hence fibrosis 
progression[23]. For instance, in a case-control study, 
Moreso et al[100] confirmed the lower prevalence of 
subclinical inflammation associated with a regimen 
based on tacrolimus, mycophenolate mofetil, and 
prednisone than with a regimen based on cyclosporine, 
mycophenolate mofetil, and prednisone. In addition, 
lower exposure to tacrolimus between 3 and 12 mo 
after transplantation was independently associated with 
higher increases in chronic pathology in patients also 
treated with mycophenolate mofetil, and prednisone[101]. 
In the liver transplantation setting, de novo DSA 
prevention strategies also include a strict adherence to 
immunosuppression and the use of tacrolimus (rather 
than cyclosporine)[5,102,103].
The treatment of acute AMR in ABO-compatible 
liver transplants is not clearly determined because 
of the limited number of cases[34,104]. Most of the 
evidence in this field derives from studies in kidney 
transplantation where different anti-humoral therapies 
similar those mentioned above have been used. 
Bortezomib, a proteasome inhibitor effective in de-
pleting plasma cells that in turn are responsible of 
producing the offending Abs, has been successfully 
used in three cases of severe AMR in ABO-compatible 
LT recipients[104]; however, concerns have been raised 
about the anti-humoral therapies in LT recipients 
because of their potent immunosuppressive effects 
that may exacerbate chronic viral hepatitis or increase 
infectious risks. Thus, experts currently advise that 
a strategy based on the combination of avoidance/
prevention when possible may be the best strategy[34].
CONCLUSION
There has been a recent resurgence of interest in 
AMR in liver transplantation based on an increasingly 
number of reports indicating DSA-mediated allograft 
dysfunction and a better characterization of this entity 
in terms of diagnostic tools and diagnostic criteria. 
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Although AMR is a less frequent cause of liver allograft 
dysfunction, it must be taken into account not only 
from a diagnostic/therapeutic point of view but also 
from a preventive standpoint.
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